| News
Bachem builds its largest production building
11.11.2021
Bachem has laid the foundation stone for its largest production building to date. The company specializing in the manufacture of peptides and oligonucleotides will initially create up to 150 new skilled jobs with this. This will strengthen the position of Bubendorf, located in the Basel Area, as a center of excellence.

Bachem is specializing in the manufacture of peptides and oligonucleotides (img: Bachem)
Bachem has started construction of the world’s most high-tech production building for peptides and oligonucleotides at its location in Bubendorf in the canton of Basel-Landschaft. The foundation stone was laid on Thursday. According to a press release, the building should expand the production capacities for these complex molecules by 2024 at the latest. These substances are used in medicinal products used to treat various diseases.
In a first phase, up to 150 positions, most of which will be highly skilled, are to be created there. The listed company has invested over 150 million Swiss francs and created 400 new jobs at its two sites in Bubendorf and Vionnaz (in the canton of Valais) over the past five years. The new production building will now strengthen the Bubendorf site’s position as a “leading center of excellence for the manufacture of complex pharmaceutical active ingredients” according to the press release. Additionally, it represents a clear commitment to Switzerland and Basel Area as a location.
Since global demand for these molecules is constantly increasing, Bachem is already looking for a third production site in Switzerland. The land reserves at the Bubendorf site will be exhausted in the medium term.
The company celebrated its 50th anniversary this year. CEO Thomas Meier is delighted that the foundation stone was laid on Swiss National Future Day, which is a day for young people to learn about working in a company. Meier adds: “Our success is founded on our ability to invest into our company efficiently and with foresight, but also on the ability to excite new generations for the impact chemistry and the natural sciences can have.”
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
BeiGene opens European headquarters in Basel
BeiGene has opened its new European headquarters in Basel. The global biotech specializing in innovative cancer treatments intends to build...
Read MoreThe 25 Best AI Courses in the Basel Area, Germany and France
Artificial Intelligence (AI) offers numerous possible applications. But how, where and regarding which focal points can you get further training...
Read MoreEngimmune Therapeutics banks 15.5 million Swiss francs
Engimmune Therapeutics will now be in a position to drive forward its innovative platforms for the development of T-cell therapies...
Read MoreBionter receives 3 million US dollars in investments
Bionter AG has received 3 million US dollars in a seed funding round. These funds will enable Bionter to bring...
Read MoreResistell seeking to further develop test to combat antibiotic resistance
The startup Resistell has launched a study looking into the applicability of a test against antibiotic resistances that is being...
Read MoreBiotech startup Cimeio receives 46 million Swiss francs for cell therapy
Cimeio Therapeutics from Basel has received initial financing amounting to 46 million Swiss francs from Versant Ventures. The startup is...
Read More